PPI - Radically Pragmatic
  • Donate
Skip to content
  • Home
  • About
    • About Us
    • Locations
    • Careers
  • People
  • Projects
  • Our Work
  • Events
  • Donate

Our Work

Press Release: PPI Releases Policy Memo Revealing FDA Regulations Struggling to Keep Up With the Digital Age

  • October 30, 2014
  • The Progressive Policy Institute

WASHINGTON—The amount of regulation on the pharmaceutical industry has increased 40 percent since 2000, according to a policy memo released today by the Progressive Policy Institute (PPI). Moreover, some new draft regulations proposed by the Food and Drug Administration (FDA) this year fail to embrace data-driven innovation.

In FDA Regulation in the Data-Driven Economy, PPI Economist Diana Carew details new regulations proposed by the FDA designed for a slower, information-poor age. The memo concludes with policy recommendations for how the FDA can improve outcomes while still protecting consumers in a data-driven economy.

“In a data-driven economy, regulators should encourage greater information sharing, instead of pre-emptively regulating information in a way that controls and ultimately restricts it,” Carew writes. “Regulators should take the role of watchful guardians over data and information flows, taking action when there is evidence of harm or injury.”

“We hope that regulators within the FDA and across other regulatory agencies will be able to use this example as a guide for approaching future regulatory questions surrounding data. Embracing the data-driven economy is the best way to promote future prosperity and well-being for all Americans.”

The memo focuses on one draft FDA guidance in particular, issued in February 2014, entitled “Guidance 
for Industry: Distributing Scientific and
 Medical Publications on Unapproved New Uses— Recommended Practices,” which lays out a lengthy list of rules and restrictions for how drug and medical device manufacturers are allowed to communicate with healthcare professionals and “healthcare entities,” such as hospitals, on unapproved new uses. It discusses the draft guidance and explains why it is not adequate for the digital age. Finally, recommendations for the draft guidance are provided, and the memo concludes with an expansion of the discussion to how this case study can serve as an example for regulators struggling with rulemaking in this time of unprecedented economic transformation.

PPI has undertaken extensive research on regulation in the 21st century, aimed at guiding regulators and policymakers through this transition. Our work strives to strike the right balance between protecting consumers and encouraging innovation in an interconnected world.

Download FDA Regulation in the Data-Driven Economy

Related Work

Op-Ed  |  January 16, 2026

Weinstein Jr. for Real Clear Markets: Stablecoin Rewards and Their Quiet Threat to Community Banking

  • Paul Weinstein Jr.
Blog  |  January 14, 2026

A Smarter Path Forward on Premium Tax Credits

  • Nate Morris
Publication  |  January 14, 2026

Building Trust Through Transparency: A New Federal Framework for Autonomous Vehicle Safety

  • Andrew Fung Alex Kilander Aidan Shannon
Press Release  |  January 13, 2026

Proposed Credit Card Rate Cap Risks Cutting Off Millions of Borrowers

  • Andrew Fung Alex Kilander Paul Weinstein Jr.
Press Release  |  December 11, 2025

New PPI Report Uncovers Billions in Hidden Costs from Federal Debit Fee Cap

  • Robert J. Shapiro Jerome Davis
Publication  |  December 11, 2025

The Unanticipated Costs and Consequences of Federal Reserve Regulation of Debit Card Interchange Fees

  • Robert J. Shapiro Jerome Davis
  • Never miss an update:

  • Subscribe to our newsletter
PPI Logo
  • Twitter
  • LinkedIn
  • Facebook
  • Donate
  • Careers
  • © 2026 Progressive Policy Institute. All Rights Reserved.
  • |
  • Privacy Policy
  • |
  • Privacy Settings